Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, our revenue amounted to SEK 15.3 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
Read our social media policy at https://www.sobi.com/en/social-media-policy
You can find out more about Sobi at https://www.youtube.com/c/sobipharma
orphan drugs, hereditary metabolic disorders, haemophilia, biopharmaceuticals, patient access, rare diseases, haematology, hematology, immunology, autoimmune